Adenocarcinoma
MONDO:0004970A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Also known as: adenocarcinoma, adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas, ADNOS
7762 clinical trials for this condition and its sub-types, 186 tagged with Adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adenocarcinoma
-
Hepatocellular carcinoma 1,045 trials · 1,090 incl. sub-types
8 sub-types
- Hepatoblastoma 42 trials Sub-types →
- Pediatric hepatocellular carcinoma 36 trials
- Fibrolamellar hepatocellular carcinoma 15 trials Sub-types →
- Adult hepatocellular carcinoma 12 trials
- Aflatoxin-related hepatocellular carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Sclerosing hepatic carcinoma 0 trials
-
Pancreatic adenocarcinoma 496 trials · 929 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Renal cell carcinoma 611 trials · 710 incl. sub-types
11 sub-types
- Renal cell adenocarcinoma 98 trials · 251 incl. sub-types Sub-types →
- Nonpapillary renal cell carcinoma 156 trials · 246 incl. sub-types Sub-types →
- Adrenal cortex carcinoma 42 trials Sub-types →
- Collecting duct carcinoma 18 trials
- Kidney medullary carcinoma 10 trials · 13 incl. sub-types Sub-types →
- MIT family translocation renal cell carcinoma 6 trials Sub-types →
- Wolffian duct adenocarcinoma 2 trials
- Acquired cystic disease-associated renal cell carcinoma 0 trials
- Cystic renal cell carcinoma 0 trials
- Mucinous tubular and spindle renal cell carcinoma 0 trials
- Renal pelvis adenocarcinoma 0 trials
-
Tubular adenocarcinoma 0 trials · 558 incl. sub-types
4 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Invasive tubular breast carcinoma 5 trials
- Gastric tubular adenocarcinoma 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Colorectal adenocarcinoma 247 trials · 548 incl. sub-types
5 sub-types
- Rectum adenocarcinoma 232 trials · 233 incl. sub-types Sub-types →
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Colorectal serrated adenocarcinoma 1 trial
- Colorectal medullary carcinoma 0 trials Sub-types →
-
Gastroesophageal junction adenocarcinoma 507 trials
-
Gastric adenocarcinoma 449 trials · 481 incl. sub-types
9 sub-types
- Microinvasive gastric cancer 28 trials
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Gastric cardia adenocarcinoma 4 trials
- Signet ring cell gastric adenocarcinoma 2 trials
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome 0 trials
- Gastric intestinal type adenocarcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Gastric tubular adenocarcinoma 0 trials
- Mucinous gastric adenocarcinoma 0 trials
-
Bile duct adenocarcinoma 17 trials · 419 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
-
Prostate adenocarcinoma 298 trials
2 sub-types
- Prostate adenoid cystic carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
-
Breast adenocarcinoma 36 trials · 279 incl. sub-types
13 sub-types
- Breast ductal adenocarcinoma 19 trials · 192 incl. sub-types Sub-types →
- Breast lobular carcinoma 13 trials · 34 incl. sub-types Sub-types →
- Inflammatory breast carcinoma 29 trials
- Lobular breast carcinoma in situ 27 trials
- Mixed lobular and ductal breast carcinoma 1 trial Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast malignant eccrine spiradenoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Mammary Paget disease 0 trials Sub-types →
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Serous adenocarcinoma 6 trials · 242 incl. sub-types
6 sub-types
- Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types Sub-types →
- Fallopian tube serous adenocarcinoma 71 trials
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
-
Ovarian adenocarcinoma 12 trials · 231 incl. sub-types
7 sub-types
- Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types Sub-types →
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Krukenberg carcinoma 1 trial
- Rete ovarii adenocarcinoma 0 trials
-
Clear cell adenocarcinoma 14 trials · 201 incl. sub-types
11 sub-types
- Clear cell renal carcinoma 140 trials · 142 incl. sub-types Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Urethra clear cell adenocarcinoma 1 trial
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Glycogen-rich clear cell breast carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
-
Esophageal adenocarcinoma 170 trials · 174 incl. sub-types
3 sub-types
- Barrett adenocarcinoma 6 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Mucoepidermoid esophageal carcinoma 0 trials
-
Adenocarcinoma in situ 10 trials · 170 incl. sub-types
3 sub-types
- Ductal breast carcinoma in situ 152 trials Sub-types →
- Lobular breast carcinoma in situ 27 trials
- Lung adenocarcinoma in situ 1 trial
-
Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 56 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Endometrium adenocarcinoma 30 trials · 119 incl. sub-types
9 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Endometrial mixed adenocarcinoma 10 trials
- Endometrial mucinous adenocarcinoma 2 trials
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types
3 sub-types
- Thyroid gland follicular carcinoma 20 trials · 77 incl. sub-types Sub-types →
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Thyroid gland mucoepidermoid carcinoma 0 trials
-
Lung adenocarcinoma 114 trials · 117 incl. sub-types
11 sub-types
- Minimally invasive lung adenocarcinoma 9 trials Sub-types →
- Lung adenocarcinoma in situ 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar lung adenocarcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Lung combined type small cell adenocarcinoma 0 trials
- Lung occult adenocarcinoma 0 trials
- Papillary lung adenocarcinoma 0 trials
- Solid adenocarcinoma with mucin production 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Gastroesophageal adenocarcinoma 93 trials
-
Papillary adenocarcinoma 2 trials · 93 incl. sub-types
11 sub-types
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Papillary renal cell carcinoma 26 trials · 28 incl. sub-types Sub-types →
- Ovarian serous surface papillary adenocarcinoma 2 trials
- Breast papillary carcinoma 1 trial Sub-types →
- Papillary eccrine carcinoma 1 trial Sub-types →
- Fallopian tube papillary adenocarcinoma 0 trials
- Gallbladder papillary neoplasm with an associated invasive carcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Papillary cystadenocarcinoma 0 trials Sub-types →
- Papillary lung adenocarcinoma 0 trials
- Papillary thymic adenocarcinoma 0 trials
-
Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types
5 sub-types
- Fallopian tube serous adenocarcinoma 71 trials
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Fallopian tube mucinous adenocarcinoma 9 trials
- Fallopian tube papillary adenocarcinoma 0 trials
-
Small intestine adenocarcinoma 18 trials · 60 incl. sub-types
2 sub-types
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
- Jejunal adenocarcinoma 0 trials
-
Mucinous adenocarcinoma 18 trials · 57 incl. sub-types
17 sub-types
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Fallopian tube mucinous adenocarcinoma 9 trials
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Endometrial mucinous adenocarcinoma 2 trials
- Mucoepidermoid carcinoma 2 trials Sub-types →
- Breast mucinous carcinoma 1 trial Sub-types →
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Acinar prostate mucinous adenocarcinoma 0 trials
- Colloid carcinoma of the pancreas 0 trials
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Gallbladder mucinous adenocarcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Mucinous gastric adenocarcinoma 0 trials
- Mucinous pancreas adenocarcinoma 0 trials
- Salivary gland mucinous adenocarcinoma 0 trials
-
Adenoid cystic carcinoma 47 trials · 48 incl. sub-types
17 sub-types
- Paranasal sinus adenoid cystic carcinoma 5 trials Sub-types →
- Salivary gland adenoid cystic carcinoma 3 trials Sub-types →
- Bartholin gland adenoid cystic carcinoma 0 trials
- Adenoid cystic breast carcinoma 0 trials
- Adenoid cystic carcinoma of oropharynx 0 trials
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Cervical adenoid cystic carcinoma 0 trials
- Cutaneous adenocystic carcinoma 0 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Lacrimal gland adenoid cystic carcinoma 0 trials
- Laryngeal adenoid cystic carcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lymph node adenoid cystic carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
- Prostate adenoid cystic carcinoma 0 trials
- Tracheal adenoid cystic carcinoma 0 trials
- Vaginal adenoid cystic carcinoma 0 trials
-
Cervical adenocarcinoma 27 trials · 34 incl. sub-types
10 sub-types
- Cervical adenosquamous carcinoma 16 trials Sub-types →
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Endocervical adenocarcinoma 3 trials
- Wolffian duct adenocarcinoma 2 trials
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Cervical adenoid cystic carcinoma 0 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
- Early invasive cervical adenocarcinoma 0 trials
- Uterine ligament adenocarcinoma 0 trials Sub-types →
-
Acinar cell carcinoma 4 trials · 15 incl. sub-types
5 sub-types
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Acinic cell breast carcinoma 0 trials
- Parotid gland acinic cell carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
- Salivary gland acinic cell carcinoma 0 trials
-
Signet ring cell carcinoma 4 trials · 11 incl. sub-types
11 sub-types
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Signet ring cell gastric adenocarcinoma 2 trials
- Krukenberg carcinoma 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar prostate adenocarcinoma, signet ring variant 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Gallbladder signet ring cell adenocarcinoma 0 trials
- Pancreatic signet ring cell adenocarcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
-
Gallbladder adenocarcinoma 9 trials
4 sub-types
-
Paget disease 2 trials · 9 incl. sub-types
5 sub-types
- Extramammary Paget disease 7 trials Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Mammary Paget disease 0 trials Sub-types →
- Osteosarcoma arising in bone Paget disease 0 trials
- Scrotum Paget disease 0 trials
-
Bladder adenocarcinoma 5 trials · 8 incl. sub-types
7 sub-types
- Bladder urachal adenocarcinoma 5 trials
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Bladder mixed adenocarcinoma 1 trial
- Bladder colloid adenocarcinoma 0 trials
- Bladder colonic type adenocarcinoma 0 trials
- Bladder hepatoid adenocarcinoma 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
-
Vaginal adenocarcinoma 7 trials
1 sub-type
- Vaginal adenoid cystic carcinoma 0 trials
-
Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types
1 sub-type
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
-
Cystadenocarcinoma 0 trials · 6 incl. sub-types
6 sub-types
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Biliary cystadenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
- Papillary cystadenocarcinoma 0 trials Sub-types →
-
Vulvar adenocarcinoma 3 trials · 5 incl. sub-types
7 sub-types
- Vulval Paget disease 2 trials
- Bartholin gland adenocarcinoma 0 trials Sub-types →
- Adenocarcinoma of skene gland origin 0 trials
- Vulvar apocrine adenocarcinoma 0 trials
- Vulvar clear cell hidradenocarcinoma 0 trials
- Vulvar eccrine adenocarcinoma 0 trials Sub-types →
- Vulvar sebaceous carcinoma 0 trials
-
Parathyroid gland carcinoma 4 trials
-
Pituitary adenocarcinoma 3 trials
3 sub-types
-
Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types
3 sub-types
- Ocular sebaceous carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Sebaceous breast carcinoma 0 trials
- Vulvar sebaceous carcinoma 0 trials
-
Hepatoid adenocarcinoma 2 trials
1 sub-type
- Bladder hepatoid adenocarcinoma 0 trials
-
Mesonephric adenocarcinoma 2 trials
1 sub-type
- Wolffian duct adenocarcinoma 2 trials
-
Sweat gland carcinoma 1 trial · 2 incl. sub-types
4 sub-types
- Apocrine adenocarcinoma 2 trials Sub-types →
- Eccrine carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Cutaneous adenocystic carcinoma 0 trials
-
Urethra adenocarcinoma 1 trial · 2 incl. sub-types
1 sub-type
-
Micropapillary serous carcinoma 1 trial
-
Nasal cavity adenocarcinoma 1 trial
-
Seminal vesicle adenocarcinoma 1 trial
-
Trabecular adenocarcinoma 1 trial
-
Ureter adenocarcinoma 1 trial
-
Adenoacanthoma 0 trials
-
Epididymal adenocarcinoma 0 trials
-
Ethmoid sinus adenocarcinoma 0 trials
-
Granular cell carcinoma 0 trials
-
Intestinal type adenocarcinoma 0 trials
2 sub-types
-
Lacrimal gland adenocarcinoma 0 trials
2 sub-types
-
Maxillary sinus adenocarcinoma 0 trials
-
Middle ear adenocarcinoma 0 trials
-
Minor salivary gland adenocarcinoma 0 trials
1 sub-type
-
Rete testis adenocarcinoma 0 trials
-
Scirrhous adenocarcinoma 0 trials
-
Submandibular gland adenocarcinoma 0 trials
-
Thymus gland adenocarcinoma 0 trials
2 sub-types
- Papillary thymic adenocarcinoma 0 trials
- Thymic mucoepidermoid carcinoma 0 trials
-
Villous adenocarcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
Can a Three-Drug combo crack pancreatic Cancer's defenses?
Disease control OngoingResearchers are testing whether adding two drugs to standard chemotherapy can shrink tumors and extend life in people with metastatic pancreatic cancer. Participants receive gemcitabine and nab-paclitaxel (standard chemo), plus cemiplimab (an immunotherapy approved for skin cance…
Phase 2 • Sponsor: Columbia University • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Could a Telomere-Targeting drug revive immunotherapy in lung cancer?
Disease control OngoingThis phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…
Phase 2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New triple therapy aims to stop pancreatic Cancer's return after surgery
Disease control OngoingThis Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can sequencing immunotherapy before chemo boost stomach cancer outcomes?
Disease control OngoingThis phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab first, followed by a combination of ramucirumab and paclitaxel, can shrink tumors and delay progression in people with advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolls…
Phase 2 • Sponsor: Harry H Yoon • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New radioactive bullet targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets liver cancer in clinical trial
Disease control OngoingThis study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…
Phase 2 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for early lung cancer: targeted combo aims to stop return after surgery
Disease control OngoingThis study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Engineered immune cells target Hard-to-Treat cancers in new trial
Disease control PausedThis study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a Triple-Drug attack slow down stomach cancer?
Disease control OngoingThis phase 2 trial is testing whether a combination of trifluridine/tipiracil (Lonsurf) plus oxaliplatin, with or without the immunotherapy nivolumab, can help people with advanced HER2-negative stomach, esophageal, or gastroesophageal junction cancer. The study compares these co…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo shows promise against tough stomach cancer
Disease control OngoingThis study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to tame tough pancreatic cancer
Disease control OngoingThis early study tests whether combining two drugs, pembrolizumab (Keytruda) and lenvatinib, can help control advanced pancreatic cancer that has already been treated. Fifteen participants will receive the combination to see if it shrinks tumors. The goal is to gather initial dat…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Fluorescent dye guides Stomach-Sparing surgery for early cancer
Disease control By invitation onlyThis study tests a surgical technique for early stomach cancer that combines a camera in the abdomen (laparoscopy) with a flexible tube down the throat (endoscopy). Doctors inject a fluorescent dye near the tumor to highlight the first lymph nodes that might contain cancer. If th…
Sponsor: wangdongsheng • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New targeted drug shows promise for lung cancer with MET mutations
Disease control OngoingThis trial tested the drug tepotinib in 337 people with advanced non-small cell lung cancer that has specific MET gene changes (METex14 skipping or MET amplification). Participants took a 500 mg pill once daily. The main goal was to see if the drug could shrink tumors. The study …
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New program aims to protect cancer Patients' hearts during treatment
Disease control By invitation onlyThis study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …
Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Vaccine trains immune system to hunt down cancer cells
Disease control PausedThis trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or…
Phase 1/2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…
Phase 1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New Heat-and-Cold treatment offers hope for men with spreading prostate cancer
Disease control CancelledThis study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recover…
Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Personalized vaccine takes on pancreatic cancer in early trial
Disease control OngoingThis early-phase trial tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people whose pancreatic cancer was removed by surgery. The goal is to see if the vaccine can be made successf…
Phase 1 • Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental pill shows promise in shrinking esophageal tumors before surgery
Disease control PausedThis study tests whether adding a pill called vactosertib to standard chemoradiotherapy can improve outcomes for people with esophageal cancer. Participants take vactosertib for two weeks before and after standard treatment, then undergo surgery. The goal is to see if the drug he…
Phase 2 • Sponsor: Melissa Lumish • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Antibody-Chemo combo shows promise in slowing stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New proton therapy may reduce side effects in esophageal cancer treatment
Disease control OngoingThis study compares two radiation methods—proton beam therapy and standard intensity-modulated radiation therapy—for people with esophageal cancer. Both are given alongside chemotherapy. The goal is to see if the newer proton therapy is safer and more effective at controlling the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cocktail aims to shrink Hard-to-Treat stomach tumors
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…
Phase 2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Supercharged immune cells take on childhood cancers
Disease control OngoingThis early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control OngoingThis study tests whether adding the drugs camrelizumab and apatinib to standard chemotherapy (SOX) before surgery can help shrink tumors in people with locally advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before surgery. T…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New triple therapy shows promise in stomach cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment be…
Phase 2/3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Promising stomach cancer combo trial pulled before it even started
Disease control CancelledThis study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. Howe…
Phase 2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Family stem cells tested against deadly pancreatic cancer
Disease control Expanded access (ended)This trial tested stem cells taken from a patient's blood relative to treat pancreatic cancer, a fast-growing and often deadly disease. Only one patient was treated under a special expanded access program, which is now closed. The goal was to see if these donated stem cells could…
Sponsor: Hope Biosciences LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…
Phase 1/2 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:32 UTC
-
Brain radiation may stop cancer spread in rare bladder cancer
Prevention OngoingThis study tests whether whole brain radiation can lower the chance of brain tumors in people with small cell carcinoma of the urinary tract (including the bladder). The 31 participants have already had chemotherapy and responded well. They receive radiation to the brain for 3 we…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
A proactive care plan may help men with prostate cancer live better
Symptom relief OngoingThis trial tests a proactive care model for men with metastatic hormone-sensitive prostate cancer who are taking the drug apalutamide. The model focuses on four areas: education, prevention, management, and follow-up, to help patients understand their treatment, reduce side effec…
Sponsor: Yonghong Li • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
NCI launches 15-Year checkup for cell therapy volunteers
Knowledge-focused By invitation onlyThis study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can a simple blood test outsmart prostate cancer?
Knowledge-focused By invitation onlyThis registry study is collecting blood samples and health data from 1,000 people being evaluated for prostate cancer. The goal is to test the accuracy of a new blood-based test called PROSTest, which looks for genetic signals of prostate cancer activity. Researchers hope this te…
Sponsor: Wren Laboratories LLC • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Mini GPS in a needle could help doctors hit hidden tumors
Knowledge-focused By invitation onlyThis study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Prostate Surgery's hidden toll: study probes lasting impact on Men's lives
Knowledge-focused By invitation onlyThis study looks at men who had their prostate removed for cancer at least one year ago. Researchers want to understand how common and severe problems like urine leakage and erectile dysfunction are, and how these issues affect quality of life, self-esteem, and relationships. Par…
Sponsor: University of Valencia • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Prostate cancer surgery under the microscope: how do patients fare after a decade?
Knowledge-focused By invitation onlyThis study follows 120 men who had robot-assisted surgery for prostate cancer to see how they are doing 10 years later. Researchers will check if the cancer has come back, how common incontinence and erectile dysfunction are, and how satisfied patients feel. The goal is to unders…
Sponsor: F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
French study tracks Real-World success of combo therapy for stomach cancer
Knowledge-focused OngoingThis study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New screening could open door to T-Cell therapy for Hard-to-Treat cancers
Knowledge-focused OngoingThis study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC